These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
277 related items for PubMed ID: 16113283
1. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Harakuni T, Sugawa H, Komesu A, Tadano M, Arakawa T. Infect Immun; 2005 Sep; 73(9):5654-65. PubMed ID: 16113283 [Abstract] [Full Text] [Related]
2. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM. Am J Trop Med Hyg; 1994 Sep; 50(5 Suppl):42-54. PubMed ID: 8203723 [Abstract] [Full Text] [Related]
3. Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR. Matoba N, Kajiura H, Cherni I, Doran JD, Bomsel M, Fujiyama K, Mor TS. Plant Biotechnol J; 2009 Feb; 7(2):129-45. PubMed ID: 19037902 [Abstract] [Full Text] [Related]
4. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J, Stanford M, Sun JB, Svennerholm AM, Tengvall S. Immunol Lett; 2005 Mar 15; 97(2):181-8. PubMed ID: 15752556 [Abstract] [Full Text] [Related]
9. Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera. Xu G, Wang S, Zhuang L, Hackett A, Gu L, Zhang L, Zhang C, Wang H, Huang Z, Lu S. Vaccine; 2009 Jun 12; 27(29):3821-30. PubMed ID: 19443090 [Abstract] [Full Text] [Related]
10. Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response. Li S, Zheng W, Kuolee R, Hirama T, Henry M, Makvandi-Nejad S, Fjällman T, Chen W, Zhang J. Mol Immunol; 2009 May 12; 46(8-9):1718-26. PubMed ID: 19269688 [Abstract] [Full Text] [Related]
11. Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases. Langridge W, Dénes B, Fodor I. Curr Opin Investig Drugs; 2010 Aug 12; 11(8):919-28. PubMed ID: 20721834 [Abstract] [Full Text] [Related]
14. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects]. Carrada Bravo T. Rev Alerg; 1993 Aug 12; 40(4):91-4. PubMed ID: 8143024 [Abstract] [Full Text] [Related]
15. Immunological features and the ability of inhibitory effects on enzymatic activity of an epitope vaccine composed of cholera toxin B subunit and B cell epitope from Helicobacter pylori urease A subunit. Guo L, Li X, Tang F, He Y, Xing Y, Deng X, Xi T. Appl Microbiol Biotechnol; 2012 Mar 12; 93(5):1937-45. PubMed ID: 22134639 [Abstract] [Full Text] [Related]
17. Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin. Boberg A, Gaunitz S, Bråve A, Wahren B, Carlin N. Vaccine; 2008 Sep 19; 26(40):5079-82. PubMed ID: 18514370 [Abstract] [Full Text] [Related]